Evidence map›Paper›PMID 42886280›Full record

ArticleMolecular biology reports2026

ITF2357 exerts anti‑tumor activity in colorectal cancer via the miR‑1938/ADAM12 axis.

Ting Wang, Lingying Zhang, Zulihumaer Yakupu, Xiaojing Shi, Yusupujiang Maimaiti, Baligen Salikebai, Mairepati Mahemuti, Hongbing Xiao, Yeerbulati Daoken, Zhili Wang and 2 more

Abstract read
PubMed Publisher
In one paragraph

Article in Molecular biology reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Ting Wang *Xinjiang Key Laboratory of Biological Resources and Genetic Engineering, College of Life Science & Technology, Xinjiang University, Xinjiang, 830046, China.
Lingying Zhang *Xinjiang Key Laboratory of Biological Resources and Genetic Engineering, College of Life Science & Technology, Xinjiang University, Xinjiang, 830046, China.
Zulihumaer Yakupu *Xinjiang Key Laboratory of Biological Resources and Genetic Engineering, College of Life Science & Technology, Xinjiang University, Xinjiang, 830046, China.
Xiaojing ShiXinjiang Key Laboratory of Biological Resources and Genetic Engineering, College of Life Science & Technology, Xinjiang University, Xinjiang, 830046, China.
Yusupujiang MaimaitiXinjiang Key Laboratory of Biological Resources and Genetic Engineering, College of Life Science & Technology, Xinjiang University, Xinjiang, 830046, China.
Baligen SalikebaiXinjiang Key Laboratory of Biological Resources and Genetic Engineering, College of Life Science & Technology, Xinjiang University, Xinjiang, 830046, China.
Mairepati MahemutiXinjiang Key Laboratory of Biological Resources and Genetic Engineering, College of Life Science & Technology, Xinjiang University, Xinjiang, 830046, China.
Hongbing XiaoKhorgos's People Hospital, Khorgos City, 835221, China.
Yeerbulati DaokenKhorgos's People Hospital, Khorgos City, 835221, China.
Zhili WangKhorgos's People Hospital, Khorgos City, 835221, China.
Baoming ZhangKhorgos's People Hospital, Khorgos City, 835221, China. 790020230057@xzhmu.edu.cn.
Zeyidan JiapaerXinjiang Key Laboratory of Biological Resources and Genetic Engineering, College of Life Science & Technology, Xinjiang University, Xinjiang, 830046, China. zeyidan@xju.edu.cn.ORCID http://orcid.org/0000-0001-6447-844X

Funding

Ili Kazakh Autonomous Prefecture Science and Technology Program Project YJC2024A15
6 · The paper itself

Abstract

purposeHistone deacetylase inhibitors (HDACi) have emerged as promising anticancer agents. This study aimed to investigate the antitumor efficacy and molecular mechanism of ITF2357 (Givinostat), a novel HDACi, in colorectal cancer (CRC).

methodsIn vitro, CT26 cell viability, proliferation, colony formation, and cell cycle distribution were assessed. In vivo, a subcutaneous CT26 tumor model was established in female BALB/c mice to evaluate the antitumor effect of ITF2357. Multi-omics analysis (miRNA-seq, mRNA-seq, ATAC-seq) was performed to identify key regulatory molecules, followed by qRT-PCR, dual-luciferase reporter, and knockdown assays for mechanistic validation.

resultsITF2357 significantly inhibited CT26 cell proliferation and induced G0/G1 phase arrest. In vivo, ITF2357 suppressed tumor growth without affecting body weight or liver and kidney tissues, suggesting no obvious systemic toxicity. Multi-omics analysis revealed that ITF2357 upregulated miR-1938, which directly targeted the 3'-UTR of ADAM12. ADAM12 knockdown phenocopied the anti-proliferative and cell cycle arrest effects of ITF2357. Clinically, high ADAM12 expression correlated with poor prognosis in CRC patients.

conclusionITF2357 exerts anti-CRC activity by upregulating miR-1938 to suppress ADAM12, leading to cell cycle arrest. These findings provide new mechanistic insights into the anti-CRC effects of ITF2357 and establish a foundation for exploring its therapeutic potential in CRC.

Indexed as

Antineoplastic AgentsColorectal NeoplasmsHydroxamic AcidsMicroRNAsAnimalsCell Line, TumorCell ProliferationFemaleGene Expression Regulation, NeoplasticHumansMiceMice, Inbred BALB CXenograft Model Antitumor AssaysAntineoplastic AgentsHydroxamic AcidsMicroRNAsADAM12Cell cycleColorectal cancerITF2357MiR-1938

Identifiers

PMID42886280

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.